S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands

Ikena Oncology (IKNA) Competitors

$1.43
-0.08 (-5.30%)
(As of 02/29/2024 ET)

IKNA vs. JATT, CGTX, CDTX, PASG, LGST, CRIS, CASI, CRDF, AVRO, and QNCX

Should you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include JATT Acquisition (JATT), Cognition Therapeutics (CGTX), Cidara Therapeutics (CDTX), Passage Bio (PASG), Semper Paratus Acquisition (LGST), Curis (CRIS), CASI Pharmaceuticals (CASI), Cardiff Oncology (CRDF), AVROBIO (AVRO), and Quince Therapeutics (QNCX). These companies are all part of the "biological products, except diagnostic" industry.

Ikena Oncology vs.

Ikena Oncology (NASDAQ:IKNA) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Ikena Oncology received 24 more outperform votes than JATT Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
Ikena OncologyOutperform Votes
24
57.14%
Underperform Votes
18
42.86%
JATT AcquisitionN/AN/A

In the previous week, Ikena Oncology had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 3 mentions for Ikena Oncology and 0 mentions for JATT Acquisition. Ikena Oncology's average media sentiment score of 0.30 beat JATT Acquisition's score of 0.00 indicating that Ikena Oncology is being referred to more favorably in the media.

Company Overall Sentiment
Ikena Oncology Neutral
JATT Acquisition Neutral

Ikena Oncology currently has a consensus price target of $10.67, indicating a potential upside of 645.92%. Given Ikena Oncology's higher probable upside, research analysts clearly believe Ikena Oncology is more favorable than JATT Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ikena Oncology
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
JATT Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

86.0% of Ikena Oncology shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 6.0% of Ikena Oncology shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

JATT Acquisition has a net margin of 0.00% compared to Ikena Oncology's net margin of -327.46%. Ikena Oncology's return on equity of -42.27% beat JATT Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Ikena Oncology-327.46% -42.27% -35.28%
JATT Acquisition N/A -49.58%2.84%

JATT Acquisition has lower revenue, but higher earnings than Ikena Oncology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ikena Oncology$15.62M4.42-$68.76M-$1.62-0.88
JATT AcquisitionN/AN/A$6.85MN/AN/A

Summary

Ikena Oncology beats JATT Acquisition on 8 of the 12 factors compared between the two stocks.


Get Ikena Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IKNA vs. The Competition

MetricIkena OncologyBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$72.87M$2.66B$4.90B$7.51B
Dividend YieldN/A2.59%2.87%3.87%
P/E Ratio-0.8828.60240.0016.68
Price / Sales4.42191.533,150.78301.28
Price / CashN/A31.6495.4255.16
Price / Book0.354.324.454.54
Net Income-$68.76M-$7.81M$114.12M$211.48M
7 Day Performance7.52%4.59%4.23%2.63%
1 Month Performance5.15%14.40%8.74%5.46%
1 Year Performance-63.24%13.04%12.11%8.67%

Ikena Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JATT
JATT Acquisition
0 of 5 stars
$3.78
-3.1%
N/AN/A$65.21MN/A0.002,021Gap Up
High Trading Volume
CGTX
Cognition Therapeutics
3.0781 of 5 stars
$2.00
+2.0%
$6.00
+200.0%
+29.4%$64.24MN/A-2.5322Short Interest ↓
CDTX
Cidara Therapeutics
4.2179 of 5 stars
$0.71
-1.4%
$4.67
+558.2%
-53.1%$64.12M$64.29M-1.8273Short Interest ↓
Positive News
PASG
Passage Bio
4.1326 of 5 stars
$1.30
+0.8%
$7.00
+438.5%
+39.0%$71.27MN/A-0.6385Upcoming Earnings
LGST
Semper Paratus Acquisition
0 of 5 stars
$4.51
flat
N/A-58.0%$71.35MN/A0.002,021Positive News
Gap Up
CRIS
Curis
1.7695 of 5 stars
$10.14
-3.3%
$37.33
+268.2%
-18.1%$59.77M$10.02M-1.1349Short Interest ↑
CASI
CASI Pharmaceuticals
4.166 of 5 stars
$5.60
-3.4%
$12.00
+114.3%
+189.6%$74.60M$42.26M-1.86224Positive News
CRDF
Cardiff Oncology
2.7426 of 5 stars
$1.70
-1.7%
$13.00
+664.7%
+2.0%$75.96M$390,000.00-1.8525Short Interest ↓
News Coverage
Gap Up
AVRO
AVROBIO
2.5476 of 5 stars
$1.30
+0.8%
$3.33
+156.4%
-6.4%$57.94MN/A-13.0078Short Interest ↓
High Trading Volume
QNCX
Quince Therapeutics
0 of 5 stars
$1.35
+5.5%
N/A+40.1%$57.87MN/A0.0021

Related Companies and Tools

This page (NASDAQ:IKNA) was last updated on 3/1/2024 by MarketBeat.com Staff